172 related articles for article (PubMed ID: 15816460)
1. Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
Kinekawa F; Kubo F; Matsuda K; Fujita Y; Kobayashi M; Funakoshi F; Uchida N; Watanabe S; Tomita T; Uchida Y; Kuriyama S
Hepatogastroenterology; 2005; 52(62):471-4. PubMed ID: 15816460
[TBL] [Abstract][Full Text] [Related]
2. [Gastroesophageal reflux disease in diabetic patients].
Kinekawa F; Kubo F; Matsuda K; Inoue H; Kuriyama S
Nihon Rinsho; 2004 Aug; 62(8):1546-52. PubMed ID: 15344549
[TBL] [Abstract][Full Text] [Related]
3. Relationship between esophageal dysfunction and neuropathy in diabetic patients.
Kinekawa F; Kubo F; Matsuda K; Fujita Y; Tomita T; Uchida Y; Nishioka M
Am J Gastroenterol; 2001 Jul; 96(7):2026-32. PubMed ID: 11467628
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
5. [Gastroesophageal reflux disease in diabetic patients].
Kinekawa F; Kubo F; Matsuda K; Inoue H; Kuriyama S
Nihon Rinsho; 2007 May; 65(5):939-45. PubMed ID: 17511237
[TBL] [Abstract][Full Text] [Related]
6. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
7. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
8. Differences in esophageal corpus motility in patients with pathological and non-pathological gastroesophageal reflux.
Klopocka M; Budzyński J; Swiatkowski M; Pulkowski G; Meder A
Med Sci Monit; 2006 Sep; 12(9):CR387-92. PubMed ID: 16940933
[TBL] [Abstract][Full Text] [Related]
9. Regional differences in the manifestation of gastrointestinal motor disorders in type 1 diabetic patients with autonomic neuropathy.
Rosztóczy A; Róka R; Várkonyi TT; Lengyel C; Izbéki F; Lonovics J; Wittmann T
Z Gastroenterol; 2004 Nov; 42(11):1295-300. PubMed ID: 15558439
[TBL] [Abstract][Full Text] [Related]
10. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
11. Gastroesophageal reflux induced by white wine: the role of acid clearance and "rereflux".
Pehl C; Frommherz M; Wendl B; Pfeiffer A
Am J Gastroenterol; 2002 Mar; 97(3):561-7. PubMed ID: 11922547
[TBL] [Abstract][Full Text] [Related]
12. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
Nakagaki O; Miyoshi H; Sawada T; Atsumi T; Kondo T; Atsumi T
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):84-9. PubMed ID: 23426701
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
[TBL] [Abstract][Full Text] [Related]
14. Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats.
Hashimoto H; Satoh N; Takiguchi Y; Nakashima M
J Pharmacol Exp Ther; 1990 May; 253(2):552-7. PubMed ID: 2159998
[TBL] [Abstract][Full Text] [Related]
15. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
[TBL] [Abstract][Full Text] [Related]
16. [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
Ito A; Ishii-Nozawa R; Ibuki C; Atarashi H; Kataoka H; Takeuchi K
Yakugaku Zasshi; 2009 Oct; 129(10):1239-47. PubMed ID: 19797880
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation.
Nakamura T; Okano R; Uchiyama H; Seo Y; Okuda S
Intern Med; 1997 Jul; 36(7):479-83. PubMed ID: 9240496
[TBL] [Abstract][Full Text] [Related]
18. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kikkawa R
Biomed Pharmacother; 1995; 49(6):269-77. PubMed ID: 7579007
[TBL] [Abstract][Full Text] [Related]
19. Gastric banding interferes with esophageal motility and gastroesophageal reflux.
Suter M; Dorta G; Giusti V; Calmes JM
Arch Surg; 2005 Jul; 140(7):639-43. PubMed ID: 16027327
[TBL] [Abstract][Full Text] [Related]
20. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
